Why the study?
Cardiovascular diseases are the leading cause of mortality in the Russian Federation, and demonstrating their economic impact provides a rationale for investing in prevention and treatment.
Implementing population-level cardiovascular prevention measures in the Russian Federation could yield a massive economic benefit of 8.1 trillion rubles over 15 years through increased labor productivity and prevention of CVD deaths.
Documents substantial national CVD economic impact; supports prevention prioritization while leaving open needs for longitudinal tracking.
Cardiovascular diseases (CVDs) are the leading threat to the population health in the Russian Federation (RF), ranking first in the mortality structure. Demonstration of the economic impact of CVD is a rationale for investing in prevention and treatment. The economic damage caused by CVD in 2016 in the RF amounted to RUB 2,7 trillion, which is equivalent to 3,2% of gross domestic product (GDP). In the structure of damage by diseases, coronary artery disease occupies a leading position — RUB 1 trillion or 1,3% of GDP, while cerebrovascular diseases, stroke and myocardial infarction — RUB 560, 424 and 213,2 billion, respectively. Evaluation of cardiovascular prevention measures is not an easy task because the effect develops over a significant period of time. At the same time, various processes can affect the effect. The RF analysis showed that the potential economic effect from anti-tobacco and anti-alcohol measures, reducing salt consumption and increasing physical activity will be RUB 8,1 trillion in labor productivity increase over 15 years (equivalent to 7,8% of GDP in 2018), with most of the effect from the prevention of CVD deaths. Analyzing the economic impact of CVDs, preventive and curative measures provide a rationale for investment and is an important step in making informed decisions.
No takes yet. Share an insight, caveat, or question.
Kontsevaya et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Russian Journal of Cardiology